Lilly €200m expansion of Cork site under review

pharmafile | February 13, 2017 | News story | Manufacturing and Production, Sales and Marketing Eli Lilly, Ireland, cork 

Eli Lilly’s planned €200m investment to its manufacturing plant in Kindsdale, County Cork, is now under-review. The expansion would bring much needed investment and employment to the area and there are concerns that it could be due to Trump’s recent overtures to the pharmaceutical industry.

The manufacturing site currently employs 500 people and the planned expansion would have a knock-on effect of creating several hundred more. Ireland has thrived on the back of being open to investment after the financial crisis.

President Trump now threatens to undermine this progress with his desire to bring manufacturing jobs to the US. It was one of the major points he drove home to the pharmaceutical industry in a meeting that was held recently – the issue of job creation. He demanded that the industry bring a number of manufacturing jobs back to the US and also to increase investment in manufacturing sites.

It was a line that was met warmly by the CEOs, when improvements to the speed at which drugs can reach the market was offered in return. It is being speculated that this may be the reason behind Eli Lilly’s decision to review its investment in the Cork site. If Trump plays hardball with the manufacturing line then the delay could be to potentially divert funds to US sites.

Eli Lilly has not yet released the reason for the delay but commented that the decision will be made available at the “appropriate stage”.

Ben Hargreaves

Related Content

Astellas plans to invest over €330m in new facility in Ireland

Astellas Pharma has announced that it is preparing to submit a planning application to build …

Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo

Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an …


Eli Lilly shares data from two phase 3 tirzepatide studies

Eli Lilly has announced results from its two phase 3 tirezepatide studies in adult patients …

Latest content